Recursion Pharmaceuticals
Stock Forecast, Prediction & Price Target
Recursion Pharmaceuticals Financial Estimates
Recursion Pharmaceuticals Revenue Estimates
Recursion Pharmaceuticals EBITDA Estimates
Recursion Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $10M N/A | $39.68M 296.81% | $44.57M 12.33% | Avg: $63.02M Low: $14.55M High: $99.86M avg. 41.38% | Avg: $151.43M Low: $65.50M High: $307.60M avg. 140.29% | ||
Net Income
% change YoY
| $-178.07M N/A | $-239.42M -34.45% | $-328.06M -37.02% | Avg: $-472.57M Low: $-706.70M High: $-245.26M avg. -44.04% | Avg: $-347.15M Low: $-519.86M High: $-58.27M avg. 26.54% | ||
EBITDA
% change YoY
| $-182.77M N/A | $-245.72M -34.44% | $-299.56M -21.91% | Avg: $-63.02M Low: $-99.86M High: $-14.55M avg. 78.96% | Avg: $-151.43M Low: $-307.60M High: $-65.50M avg. -140.29% | ||
EPS
% change YoY
| -$1.05 N/A | -$1.36 -29.52% | -$1.58 -16.17% | Avg: -$1.8 Low: -$3.4 High: -$1.18 avg. -13.61% | Avg: -$1.07 Low: -$2.5 High: -$0.28 avg. 40.47% | ||
Operating Expenses
% change YoY
| $192.77M N/A | $237.13M 23.01% | $352.04M 48.46% | Avg: $362.84M Low: $83.81M High: $574.98M avg. 3.06% | Avg: $871.88M Low: $377.17M High: $1.77B avg. 140.29% | ||
FAQ
What is Recursion Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -8.75% in 2025-2026.
We have gathered data from 5 analysts. Their low estimate is -706.70M, average is -472.57M and high is -245.26M.
What is Recursion Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 90.83% in 2025-2026.
We have gathered data from 6 analysts. Their low revenue estimate is $14.55M, average is $63.02M and high is $99.86M.
What is Recursion Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 13.42% in 2025-2026.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$3.4, average is -$1.8 and high is $-1.18.
What is the best performing analyst?
In the last twelve months analysts have been covering Recursion Pharmaceuticals stock. The most successful analyst is Scott Schoenhaus.